Search results
Results from the WOW.Com Content Network
Supply problems and insurance complications have made it difficult for people to start — and stay on — Wegovy and similar medications that are transforming obesity treatment, according to ...
Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday. "In our guidance for the full ...
The US Food and Drug Administration approved Wegovy in 2021 for chronic weight management for people with a body mass index of 30 or more, or 27 or more for those with a weight-related condition ...
More than 200,000 prescriptions for copies of Novo Nordisk's weight-loss drug Wegovy are getting filled by U.S. patients each month, an industry group told the U.S. drugs regulator in a letter ...
(Reuters) -The U.S. Food and Drug Administration's website showed on Monday one dose of Novo Nordisk's weight-loss drug Wegovy as available after being in short supply, while three other doses ...
Novo has been unable to meet runaway demand for Wegovy, and in May began limiting the number of U.S. patients who could start treatment by reducing supply of the lowest three doses of the appetite ...
The company also stated that Ozempic’s net price has gone down by 40% since it was introduced in the U.S. Wegovy, too, is “following a similar trajectory.”
Novo shares were trading 1.6% higher at 1038 GMT, even as investors and analysts had hoped for clarity on when limits on the supply of Wegovy starter doses in the U.S. would cease.